Skip to main content
Equibles
MNOV logo

MNOV · Medicinova Inc

Track MNOV — free

Use MNOV with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research MNOV.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$1.36 -0.04 (-2.86%) At close · Oct 20
Rebalance outlook locked
Market Cap
$68.91M
Shares
49.22M
Volume · Oct 20 37.12K Avg daily vol (3M) 322.6K

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$1.36 Open$1.40 Day$1.36–1.44 52W close$1.18–3.45 Avg vol 30d651K Short int339K · 0.7% float · 1.0d Short vol37% DataJan 2020–Oct 2026 Filing10-Q · Aug 13

Up next

Latest filing: 10-Q
filed Aug 13, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$920,481
Trailing 12 months
Net income (TTM)
−$10.75M
Trailing 12 months
Revenue growth YoY
+240.6%
Year over year
Operating margin
-3,242.5%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-13.1%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+0.4%
Year over year · more shares
Price change (1Y)
+13.8%
Trailing year
Short interest
0.7%
Latest settlement · 1.0 days to cover
View all 122 metrics

Quarterly results

Revenue Net income Net loss
· $0 −$2,215 '15 Q1 · $4.00M −$187,799 '21 Q1 · $37,500 −$3.58M '21 Q3 · $1.00M −$723,107 '23 Q3 · $134,599 −$3.28M '25 Q2 · $123,319 −$3.05M '25 Q3 · $186,984 −$2.59M '26 Q1 LATEST ▲240.6% $458,439 −$2.31M '26 Q2

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Strong Sell Momentum Weak Sentiment Neutral Fundamentals Weak Quant / Vol Very High
Market backdrop VIX 17.3 · elevated Equity put/call 0.56
Technical
price trend
Strong Sell
50 / 200-day cross No cross
Price vs 200-day avg −10%
below
Price vs 50-day avg −24%
below
RSI (14) 34
neutral
MACD trend Negative
52-week position 8%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Weak
1-month return −53%
trailing
6-month return −1%
trailing
YTD return +4%
this year
Relative strength −9%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $2 › 200d $2 — 50d above 200d
Institutional flow Distributing
-3% holders QoQ · +3 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
0.69% of float · ▼ -9.5% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
29 holders — mid 3-yr range
Squeeze score 27
low risk · 0–100
Fundamentals
Weak
EPS growth −4%
Y/Y
Free cash flow $-9.8M
Balance sheet $13.8M
net cash
Quant / Vol
risk profile
Very High
Volatility 86%
annualized · 1-yr
Max drawdown −61%
past year
ATR 12.4%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Strong Sell
4 · 3 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−10% Bearish
Price vs 50-day avg
−24% Bearish
RSI (14)
34 Neutral
MACD trend
Negative Bearish
52-week position
8% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $2 › 200d $2 — 50d above 200d
Institutional flow Distributing
-3% holders QoQ · +3 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
0.69% of float · ▼ -9.5% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
29 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $1 Now $1 · 8% Range high $3
vs 200-day avg -10% vs 50-day avg -24%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
MNOV
Medicinova Inc
this stock
$68.91M +3.8% — — 0.7%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $130.07B +13.5% +46.2% 29.9 1.8%
MRNA
Moderna, Inc.
 $90.58B +720.9% +4.3% — 7.7%
REGN
Regeneron Pharmaceuticals, Inc.
 $80.51B +4.6% +20.8% 19.4 2.1%
CSLLY
Csl Ltd
 $66.34B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
29
% held
10.5%
Net QoQ
-226.4K sh
Top holder
Essex Woodlands Managemen…
Held Float
View
Held by Funds
Fund positions
16
View
Short & Settlement
Short Interest Falling
Shares short
339.1K
Days to cover
1.0d
Change
-35.6K sh
View
Short Volume
Short vol %
37%
As of
Oct 20, 2026
Short Total
View
Fails to Deliver
FTD shares
4.7K
Value
$9.0K
As of
Sep 30, 2026
View
Off-Exchange
Off-exchange %
64.8%
Week of
Sep 14, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$409.7K
Net income (FY)
$-12.0M
EPS diluted
$-0.24
View
Filings
SEC Filings
Latest
8-K
Filed
Sep 28, 2026
This year
14
View
Earnings & Events
Webcasts
Last webcast
Sep 15, 2026
View

Performance

5D 20D 120D MTD YTD
MNOV -9.3% -53.1% -0.7% -18.8% +3.8%
SPY -1.2% -0.6% +8.1% +0.8% +12.8%
vs SPY -8.2% -52.5% -8.8% -19.7% -9.0%
Key facts CIK 1226616 CUSIP 58468P206 13F (30d) 1 filings 1 filers Visit website Investor relations